Evidence map›Paper›PMID 42110631›Full record

ArticleArchives of medical science : AMS2026

Kawasaki disease in Latvia 2012-2019: epidemiology and rate of resistance to initial treatment.

Lauma Vasiļevska, Zane Dāvidsone, Elīna Ligere, Ruta Šantere, Valda Staņēviča

Abstract read
In one paragraph

Article in Archives of medical science : AMS, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Lauma VasiļevskaChildren's Clinical University Hospital, Latvia.
Zane DāvidsoneChildren's Clinical University Hospital, Latvia.
Elīna LigereChildren's Clinical University Hospital, Latvia.
Ruta ŠantereChildren's Clinical University Hospital, Latvia.
Valda StaņēvičaChildren's Clinical University Hospital, Latvia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Kawasaki disease (KD) is an acute febrile illness of early childhood, characterised by vasculitis of the coronary and medium-sized arteries. The incidence of the disease differs worldwide, but the incidence of KD has not been established in Latvia. The aim of the study was to describe the epidemiological characteristics and estimate the incidence rate and resistance to initial treatment of KD among hospitalised children in Latvia. Material and methods: The study was a descriptive, population-based study, which used hospital discharge records of patients < 18 years old diagnosed with KD in the years 2012-2019. Incidence rate was calculated using the number of KD patients and corresponding national census data. Results: There were 36 KD patients in Latvia. The median age at admission was 2.8 years, with 67% of cases under 5 years of age, and the male/female ratio was 1.3 : 1. The mean annual incidence rate was 1.3 per 100,000 children 0-18 years old, and 2.9 per 100,000 for children < 5 years old. The mean length of hospital stay was 14 days. Coronary artery dilatation was recorded in 8% of the patients (all of whom were male). Every patient received intravenous immunoglobulin (IVIG), with a median of 7 days from fever onset to IVIG administration. Refractory treatment was reported in 25% of cases. Conclusions: This is the first epidemiological study of KD in Latvia. The incidence rates are lower than those reported for other European countries. The percentage of refractory treatment was higher than in other studies.

Indexed as

IVIG treatmentKawasaki disease incidencerefractory Kawasaki disease

Identifiers

PMID42110631
PMCPMC13154788

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.